131I-Weimeisheng (131I-Tumor Necrosis Therapy mAb injection) is a radiolabeled chimeric antibody originally developed at the University of Southern California and brought on the Chinese market by the company Shanghai Meien Biotechnology and the CIRC. The drug is targeting intracellular DNA and was launched in China since 2006 for the radio-immunotherapy treatment of advanced lung cancer that cannot be controlled by radioactive chemotherapy or in patients with advanced lung cancer relapse.
Target/Mechanism: intracellular DNA
Leading Emitter: beta electrons (β–)